P&G Q4 update
This article was originally published in The Rose Sheet
Executive SummaryProcter & Gamble predicts higher than expected earnings growth for the fourth quarter ending June 30, based on strong sales volume. Core earnings, excluding restructuring charges, to be up in the high teens and volume growth forecast at 9%-10%, led by the Clairol acquisition and "strong performances by the beauty care, health care and fabric and home care business units, especially in North America," firm says. Sales, excluding foreign exchange, predicted to rise in the mid- to high-single-digit percent range. P&G will report fourth quarter and year-end results Aug. 5...
You may also be interested in...
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.